Literature DB >> 6156633

Intra-arterial chemotherapy for patients with inoperable carcinoma of the pancreas.

J C Gazet.   

Abstract

Percutaneous intra-arterial chemotherapy followed by intravenous maintenance therapy has been given to a highly selected group of 63 patients with inoperable carcinoma of the pancreas in most of whom the predominant symptom was pain. Relief of pain was an immediate response in 55%, with a slow recurrence of symptoms. Low toxicity was observed, with only one death attributable to the form of therapy used.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6156633      PMCID: PMC2492380     

Source DB:  PubMed          Journal:  Ann R Coll Surg Engl        ISSN: 0035-8843            Impact factor:   1.891


  1 in total

Review 1.  The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma.

Authors:  S K Carter; R L Comis
Journal:  Cancer Treat Rev       Date:  1975-09       Impact factor: 12.111

  1 in total
  4 in total

Review 1.  Review of general surgery 1980.

Authors:  H Ellis
Journal:  Postgrad Med J       Date:  1981-06       Impact factor: 2.401

2.  Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.

Authors:  Ali I Shamseddine; Mohammad J Khalifeh; Fadi H Mourad; Aref A Chehal; Aghiad Al-Kutoubi; Jaber Abbas; Mohammad Z Habbal; Lida A Malaeb; Anwar B Bikhazi
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Celiac axis infusion chemotherapy in advanced nonresectable pancreatic cancer.

Authors:  C A Maurer; M M Borner; J Läuffer; H Friess; K Z'graggen; J Triller; M W Büchler
Journal:  Int J Pancreatol       Date:  1998-06

4.  Relief of the pain of unresectable carcinoma of pancreas by chemical splanchnicectomy during laparotomy.

Authors:  A M Gardner; G Solomou
Journal:  Ann R Coll Surg Engl       Date:  1984-11       Impact factor: 1.891

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.